DS Biopharma - Biopharma drug discovery and development

Latest Press Releases

March 18, 2021

DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®

• Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US • DS Biopharma becomes an investor in Nuvothera and […]

March 6, 2019

Clinical Study Shows Topical DS107 Prevents Disease Exacerbation in Atopic Dermatitis Patients

Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]

More Press Releases

Publications and Media Coverage

January 19, 2021

DS BIOPHARMA ABSTRACTS ACCEPTED AT THE ATOPIC DERMATITIS CENTRE OF REFERENCE AND EXCELLENCE (ADCARE) 2021 CONFERENCE

DS Biopharma (DS) has successfully submitted two abstracts to the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference. A link to the abstract “Steroid-sparing […]

November 19, 2019

Pipeline full with agents in various phases of development | Dermatology Times

The following article appeared in Dermatology Times on 19th November 2019: https://www.dermatologytimes.com/atopic-dermatitis/pipeline-full-agents-various-phases-development As dermatologists gain experience with newer atopic dermatitis medications, they’re getting glimpses of data […]

Join our mailing list

Connect with us

Contact us

t: +353 1 2933 590
e: [email protected]

A LEADER

IN LIPID SCIENCE